PSMD4
PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
Overview
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Talazoparib and Carfilzomib. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.12, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
- 1 · What it is
PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.
- 2 · What goes wrong in cancer
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
- 3 · How drugs use it
No product in this corpus aims at PSMD4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:9561 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P55036 (protein name, function text, keywords and locations (REST API)); CIViC gene PSMD4 (2 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Breast Cancer (GraphQL API, CC0)); Open Targets ENSG00000159352 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Biology
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMD4 acts as an ubiquitin receptor subunit through ubiquitin-interacting motifs and selects ubiquitin-conjugates for destruction. Displays a preferred selectivity for longer polyubiquitin chains. Locus 1q21.3 (HGNC).
- Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693)
- Colorectal cancer: CIViC evidence names this disease
- Breast cancer: CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)
- Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 2 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PSMD4" OR ABSTRACT:"PSMD4" OR TITLE:"proteasome 26S subunit ubiquitin receptor, non-ATPase 4" OR ABSTRACT:"proteasome 26S subunit ubiquitin receptor, non-ATPase 4" OR TITLE:"26S proteasome non-ATPase regulatory subunit 4" OR ABSTRACT:"26S proteasome non-ATPase regulatory subunit 4" OR TITLE:"S5A" OR ABSTRACT:"S5A" OR TITLE:"AF-1" OR ABSTRACT:"AF-1" OR TITLE:"Rpn10" OR ABSTRACT:"Rpn10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMD4, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPSMB8
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Multiple myeloma.
- TargetADRM1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA2
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA3
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA4
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA5
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA6
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.